Biosimilars and Future Biotherapeutics

Future Biotherapeutics: Cell and Gene Therapies

The future of biotherapeutics is rapidly advancing toward a new era defined by cell and gene therapies (CGTs)—transformative modalities that go beyond symptom management to offer the possibility of long-term remission, correction of genetic defects, and even cures. Unlike traditional biologics or biosimilars that generally target disease pathways with proteins such as monoclonal antibodies, cell and gene therapies work at a deeper level by repairing, replacing, or reprogramming the body's cellular and genetic machinery. These therapies hold immense promise, particularly in treating inherited genetic disorders, hematologic malignancies, solid tumors, and rare diseases for which no curative options previously existed. By harnessing living cells or directly modifying DNA, CGTs aim to address the root cause of disease, marking a paradigm shift in medical innovation and personalized medicine. Gene therapies involve delivering genetic material—either by inserting functional genes into a patient's cells or editing defective ones using tools like CRISPR-Cas9 or zinc finger nucleases. These technologies are being explored for conditions such as spinal muscular atrophy, hemophilia, Duchenne muscular dystrophy, and certain forms of inherited blindness. Vectors, particularly adeno-associated viruses (AAVs), are used to transport the genetic payload to target cells, though newer non-viral delivery methods are also emerging. Cell therapies, on the other hand, involve the transplantation of modified or engineered cells into a patient.